Exchange: NASDAQ·Updated 05:36 AM EDT
News
all
press releases
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction...
Business Wire
More News
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
Zacks
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) PR Newswire NEW YORK, Aug. 3, 2026 NEW YORK, Aug. 3, 2026...
PR Newswire
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.read more...
Benzinga
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages...
Business Wire
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
Indivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +18.56% and +11.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Supernus, Indivior Merger Creates $2.2 Bln CNS Company; Shares Surge In Pre-market
(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN) on Monday entered into a definitive agreement to merge with Indivior Pharmaceuticals, Inc. (INDV) in an all-stock transaction...
Nasdaq News: Markets
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.
Zacks
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Zacks
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks

Advertisement|Remove ads.